Molecular biology of therapy-related leukaemias

Clinical and Translational Oncology

Volumn 12, Issue 1, 2010, Pages 8-14

  Joannides, Melanie ^a   Grimwade, David ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Alkylating agents; Therapy related AML; Topoisomerase

Indexed keywords

ALKYLATING AGENT; CELL DNA; CHLORMETHINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; EARLY GROWTH RESPONSE FACTOR 1; EPIRUBICIN; GYRASE INHIBITOR; MELPHALAN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BREAST CARCINOMA; CANCER CELL; CANCER CELL DESTRUCTION; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 21Q; CHROMOSOME 5Q; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; DNA ALKYLATION; DNA CLEAVAGE; DNA REPAIR; DNA STRAND; DNA STRUCTURE; DRUG MECHANISM; GENE MUTATION; HODGKIN DISEASE; HUMAN; KARYOTYPE; LEUKEMIA; MISMATCH REPAIR; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN CLEAVAGE; PROTEIN DNA INTERACTION; REVIEW; SECONDARY LEUKEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMOSOME BREAKAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; MOLECULAR BIOLOGY; NEOPLASMS, SECOND PRIMARY;

EID: 76049113976     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0460-5     Document Type: Review

References (62)

1. C. Kollmannsberger J.T. Hartman L. Kanz C. Bokemeyer 1998 Risk of secondary myeloid leukaemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies J Cancer Res Clin Oncol 124 207 214 10.1007/s004320050156 1:CAS:528:DyaK1cXlslOisrw%3D 9619748 (Pubitemid 28216233)
2. J.D. Rowley H.M. Golomb J.W. Vardiman 1977 Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin's lymphoma Blood 50 759 770
3. G. Leone M. Luca P. Alessandro, et al. 1999 The incidence of secondary leukaemias Haematologica 84 937 945 1:STN:280:DyaK1MvjvFOnsA%3D%3D 10509043
4. J. Pedersen-Bjergaard M.K. Andersen D.H. Christiansen C. Nerlov 2002 Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia Blood 99 1909 1912 10.1182/blood.V99.6.1909 1:CAS:528:DC%2BD38XitF2ntrk%3D 11877259 (Pubitemid 34525468)
5. N.L. Harris E.S. Jaffe J. Diebold, et al. 1999 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997 J Clin Oncol 17 3835 3849 1:STN:280:DC%2BD3c%2FksVyltQ%3D%3D 10577857
6. J.D. Rowley H. Olney 2002 International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy related myelodysplastic syndromes and acute leukemia: overview report Genes Chromosomes Cancer 33 331 345 10.1002/gcc.10040 11921269 (Pubitemid 34208796)
7. H.G. Ahuja C.A. Felix P.D. Aplan 2000 Potential role of DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations Genes Chromosomes Cancer 29 96 105 10.1002/1098-2264(2000)9999:9999<::AID- GCC1013>3.0.CO;2-T 1:CAS:528:DC%2BD3cXntVWiurw%3D 10959088 (Pubitemid 30679667)
8. J. Pedersen-Bjergaard M.K. Andersen M.T. Andersen D.H. Christiansen 2008 Genetics of therapy related myelodysplasia and acute myeloid leukemia Leukemia 22 240 248 10.1038/sj.leu.2405078 1:CAS:528:DC%2BD1cXhvVyltb4%3D 18200041 (Pubitemid 351250527)
9. Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
10. P.M. Carli C. Sgro N. Parchin-Geneste, et al. 2000 Increase therapy-related leukemia secondary to breast cancer Leukemia 14 1014 1017 10.1038/sj.leu.2401787 1:CAS:528:DC%2BD3cXksVCmurg%3D 10865966
11. M. Beaumont M. Sanz P.M. Carli, et al. 2003 Therapy-related acute promyelocytic leukemia J Clin Oncol 21 2123 2137 10.1200/JCO.2003.09.072 1:CAS:528:DC%2BD2cXpsVGqtbs%3D 12775738 (Pubitemid 46606361)
12. M.A. Sanz D. Grimwade M.S. Tallman, et al. 2009 Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet Blood 113 1875 1891 10.1182/blood-2008-04-150250 1:CAS:528:DC%2BD1MXivVaqsLY%3D 18812465
13. Grimwade D, Hills RK (2009) Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 385-395
14. Hartwell LH, Hood L, Goldberg ML et al (2006) Genetics: from genes to genomes, 3rd edn. McGraw-Hill Science, New York
15. N. Osheroff L.E. Zechiedrich K.C. Gale 1991 Catalytic function of DNA topoisomerase II BioEssays 13 269 273 10.1002/bies.950130603 1:CAS:528:DyaK3MXltlSgtLk%3D 1654050
16. K. McClendin N. Osheroff 2007 DNA topoisomerase II, genotoxicity, and cancer Mutat Res 623 83 97
17. A. Burden N. Osheroff 1998 Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim Biophys Acta 1400 139 154 1:CAS:528:DyaK1cXmtFWisrg%3D 9748545
18. E.L. Zechiedrich N. Osheroff 1990 Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers EMBO J 9 4555 4562 1:CAS:528:DyaK3MXnslGrtQ%3D%3D 2176156
19. P.J. Hagerman 1988 Flexibility of DNA Annu Rev Biophys Chem 17 265 286 10.1146/annurev.bb.17.060188.001405 1:CAS:528:DyaL1cXltVKmtbw%3D
20. J.R. Spitzner M.T. Muller 1988 A consensus sequence for cleavage by vertebrate DNA topoisomerase II Nucleic Acids Res 16 5533 5556 10.1093/nar/16.12.5533 1:CAS:528:DyaL1cXlt1Crtb4%3D 2838820
21. J.E. Deweese N. Osheroff 2008 The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res 37 738 748 10.1093/nar/gkn937 19042970
22. J.E. Deweese M.A. Osheroff N. Osheroff 2009 DNA topology and topoisomerases: teaching a knotty subject Biochem Mol Biol Educ 37 2 10 10.1002/bmb.20244 1:CAS:528:DC%2BD1MXhs1Kms7s%3D
23. B.C. Baguley L.R. Ferguson 1998 Mutagenetic properties of topoisomerase-targeted drugs Biochim Biophys Acta 1400 213 222 1:CAS:528:DyaK1cXmtFWis7g%3D 9748584
24. M. Sander T. Hsieh 1982 Double strand DNA cleavage by type ll DNA topoisomerase from Drosophila melanogaster J Biol Chem 285 8421 8428
25. B.U. Muller J.R. Spitzner J.A. DiDonato, et al. 1988 Single-strand DNA cleaves by eukaryotic topoisomerase ll Biochemistry 27 8369 8379 10.1021/bi00422a012 1:CAS:528:DyaL1cXlvVKjs7g%3D 2853964 (Pubitemid 18262756)
26. L.F. Liu T.C. Rowe L. Yang, et al. 1983 Cleavage of DNA by mammalian DNA topoisomerase ll J Biol Chem 258 15365 15370 1:CAS:528:DyaL3sXmtVylurw%3D 6317692
27. C.A. Felix 2001 Leukemias related to treatment with DNA topoisomerase II inhibitors Med Pediatr Oncol 36 525 535 10.1002/mpo.1125 1:STN:280: DC%2BD3MzgvFGitA%3D%3D 11340607 (Pubitemid 32336557)
28. J.M. Allan L.B. Travis 2005 Mechanisms of therapy related carcinogenesis Nat Rev 5 943 955 1:CAS:528:DC%2BD2MXht1ykurbJ
29. H. Mori S.M. Colman Z. Xiao, et al. 2002 Chromosome translocations and covert leukemic clones are generated during normal fetal development Proc Natl Acad Sci U S A 99 8242 8247 10.1073/pnas.112218799 1:CAS:528: DC%2BD38XkvVGhtb8%3D 12048236 (Pubitemid 34651037)
30. J. Basecke L. Cepek C. Mannhalter, et al. 2002 Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia Blood 100 2267 2268 10.1182/blood-2002-06-1673 1:CAS:528:DC%2BD38Xnt1yhtro%3D 12229881 (Pubitemid 35001270)
31. M. Stanulla J. Wang D.S. Chervinsky, et al. 1997 DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis Mol Cell Biol 17 4070 4079 1:CAS:528:DyaK2sXktFOhurc%3D 9199342
32. C.J. Betti M.J. Villalobos M.O. Diaz A.T. Vaughan 2001 Apoptotic triggers initiate translocations within the MLL gene involving non-homologous end joining repair system Cancer Res 61 4550 4555 1:CAS:528:DC%2BD3MXktlWjsLw%3D 11389089
33. S.P. Sim L.F. Liu 2001 Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis J Biol Chem 276 31590 31595 10.1074/jbc.M103962200 1:CAS:528:DC%2BD3MXms1Snu70%3D 11406628
34. C.J. Betti M.J. Villalobos M.O. Diaz A.T. Vaughan 2003 Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division Cancer Res 63 1377 1381 1:CAS:528:DC%2BD3sXit1Sgurs%3D 12649202
35. C.A. Felix C.P. Kolaris N. Osheroff 2006 Topoisomerase II and the etiology of chromosomal translocations DNA Repair (Amst) 5 1093 1108 10.1016/j.dnarep.2006.05.031 1:CAS:528:DC%2BD28XptFSrtr8%3D (Pubitemid 44291622)
36. B.D. Lovett D. Strumberg I.A. Blair, et al. 2001 Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints Biochemistry 40 1159 1170 10.1021/bi002361x 1:CAS:528: DC%2BD3MXivVamtA%3D%3D 11170441 (Pubitemid 32142877)
37. B.D. Lovett L. Lo Nigro E.F. Rappaport, et al. 2001 Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation Proc Natl Acad Sci U S A 98 9802 9807 10.1073/pnas.171309898 1:CAS:528:DC%2BD3MXmtlCms7Y%3D 11493704 (Pubitemid 32769384)
38. R.J. Whitmarsh C. Saginario Y. Zhuo, et al. 2003 Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing Oncogene 22 8448 8459 10.1038/sj.onc.1207052 1:CAS:528: DC%2BD3sXptVOrtL8%3D 14627986 (Pubitemid 37523897)
39. A.R. Mistry C.A. Felix R.J. Whitmarsh, et al. 2005 DNA topoisomerase II in therapy related acute promyelocytic leukemia N Engl J Med 352 1529 1538 10.1056/NEJMoa042715 1:CAS:528:DC%2BD2MXjtFGnsLw%3D 15829534 (Pubitemid 40517093)
40. J.M. Fortune N. Osheroff 2000 Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog Nucleic Acid Res Mol Biol 64 221 253 10.1016/S0079-6603(00)64006-0 1:CAS:528:DC%2BD3cXivVCnsLw%3D 10697411
41. S.K. Hasan A.N. Mays T. Ottone, et al. 2008 Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis Blood 112 3383 3390 10.1182/blood-2007-10- 115600 1:CAS:528:DC%2BD1cXht1Omur3L 18650449
42. Mays AN, Osheroff N, Xiao Y et al (2009) Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood [Epub ahead of print]
43. R.G. Ghalie E. Mauch G. Edan, et al. 2002 A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis Mult Scler 8 441 445 10.1191/1352458502ms836oa 1:CAS:528:DC%2BD38XnvVWjtbY%3D 12356214 (Pubitemid 35041466)
44. J. Pedersen-Bjergaard L. Specht S.O. Larsen, et al. 1987 Risk of therapy-related leukaemia and preleukaemia after Hodgkins disease. Relation to age, cumulative dose of alkylating agents and time from chemotherapy Lancet 2 83 88 10.1016/S0140-6736(87)92744-9 1:STN:280:DyaL2s3ls1GjtA%3D%3D 2885581
45. R. Saffhill G.P. Margison P.J. O'Connor 1985 Mechanisms of carcinogenesis induced by alkylating agents Biochim Biophys Acta 823 111 145 1:CAS:528:DyaL28Xhs1Wgsg%3D%3D 3907708
46. S.M. Davis 2001 Therapy-related leukemia associated with alkylating agents Med Paediatr Oncol 36 536 540 10.1002/mpo.1126 (Pubitemid 32336558)
47. L.J. Worrillow J.M. Allan 2006 Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia Oncogene 25 1709 1720 10.1038/sj.onc.1209208 1:CAS:528:DC%2BD28XitlKntbs%3D 16278672
48. P. Brooks P.D. Lawley 1961 The reaction of mono- and di-functional alkylating agents with nucleic acids Biochem J 80 496 503
49. S.G. Chaney A. Sancar 1996 DNA repair: enzymatic mechanism and relevance to drug response J Natl Cancer Inst 88 1346 1360 10.1093/jnci/88.19.1346 1:CAS:528:DyaK28XmsFOkt7k%3D 8827012
50. F. Drablos E. Feyzi P.A. Aas, et al. 2004 Alkylation damage in DNA and RNA-repair mechanism and medical significance DNA Repair (Amst) 3 1389 1407 10.1016/j.dnarep.2004.05.004 1:CAS:528:DC%2BD2cXnsleitb4%3D (Pubitemid 39221738)
51. E.J. Dann R.M. Rowe 2001 Biology and therapy of secondary leukaemias Best Pract Res Clin Haematol 14 119 137 10.1053/beha.2000.0119 1:CAS:528: DC%2BD38XhvFagtg%3D%3D 11355927 (Pubitemid 32372403)
52. R.A. Kyle R.V. Pierre E.D. Bayrd 1975 Multiple myeloma and acute leukaemia associated with alkylating agents Arch Intern Med 135 185 192 10.1001/archinte.135.1.185 1:STN:280:DyaE2M%2FovFKiuw%3D%3D 1053891
53. P. Karran J. Offman M. Bignami 2003 Human mismatch repair, drug-induced DNA damage, and secondary cancer Biochemie 85 1149 1160 10.1016/j.biochi.2003. 10.007 1:CAS:528:DC%2BD2cXjsVyqsg%3D%3D (Pubitemid 38142368)
54. M.A. Smith R.P. McCaffrey J.E. Karp 1996 The secondary leukaemias: challenges and research directions J Natl Cancer Inst 88 407 413 10.1093/jnci/88.7.407 1:STN:280:DyaK287nslyqsg%3D%3D 8618232 (Pubitemid 26097057)
55. B.L. Ebert 2009 Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer Leukemia 23 1252 1256 10.1038/leu.2009.53 1:CAS:528:DC%2BD1MXoslOhs7o%3D 19322210
56. T.X. Liu M.W. Becker J. Jelinek, et al. 2007 Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation Nat Med 13 78 83 10.1038/nm1512 17159988 (Pubitemid 46067389)
57. B.L. Ebert J. Pretz J. Bosco, et al. 2008 Identification of RPS14 as a 5q-syndrome gene by RNA interference screen Nature 451 335 339 10.1038/nature06494 1:CAS:528:DC%2BD1cXnt1Gjtw%3D%3D 18202658
58. Starczynowski DT, Kuchenbauer F, Argiropoulos B et al (2009) Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med [Epub ahead of print]
59. D.H. Christiansen M.K. Andersen J. Pedersen-Bjergaard 2001 Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukaemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and poor prognosis J Clin Oncol 19 1405 1413 1:CAS:528:DC%2BD3MXit1ertL8%3D 11230485
60. C.H. Pui C. Riberio M.L. Hancock, et al. 1991 Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia N Engl J Med 325 1682 1687 1:STN:280:DyaK38%2FkvFKiuw%3D%3D 1944468
61. C. Praga J. Bergh J. Bliss, et al. 2005 Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide J Clin Oncol 23 4179 4191 10.1200/JCO.2005.05.029 1:CAS:528:DC%2BD2MXmt1els7s%3D 15961765 (Pubitemid 46211324)
62. C. Seedhouse N. Russell 2007 Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia Br J Haematol 137 513 529 10.1111/j.1365-2141.2007.06613.x 1:CAS:528:DC%2BD2sXot1KqsLw%3D 17539774 (Pubitemid 46817341)